A Preventable Tragedy, The Urgent Need to Overhaul India’s Fractured Drug Regulatory System

A Preventable Tragedy, The Urgent Need to Overhaul India’s Fractured Drug Regulatory System

In the autumn of 1937, a wave of horror swept across the United States. The S.E. Massengill Company, in a bid to make its new “Elixir Sulfanilamide” more palatable for children, used a toxic industrial solvent, diethylene glycol (DEG), to dissolve the drug. No safety tests were conducted. The result was the agonizing deaths of 107 people, many of them children. The public outcry was so profound, the letters from grieving parents to President Franklin D. Roosevelt so heart-wrenching, that it spurred a nation into action. Within a year, the U.S. Congress passed the landmark Federal Food, Drug, and Cosmetic Act of 1938, transforming the Food and Drug Administration (FDA) from a reactive body into a proactive guardian of public health, mandated to ensure drug safety before products could reach the market.

Nearly nine decades later and thousands of miles away, history has repeated itself with a devastating and sickening familiarity. From the second half of August 2025, the same toxic chemical, DEG, has claimed the lives of at least 16 children in Chhindwara, Madhya Pradesh. They were administered ‘Coldrif’, a cough syrup manufactured by Tamil Nadu-based Sresan Pharma. This is not an isolated incident. It is the latest chapter in a long and shameful saga of Indian medicines killing Indians. The 1937 American tragedy became a catalyst for revolutionary change. The question that now hangs over India is whether the deaths of its children in Chhindwara will finally provoke the same level of national horror, outrage, and, most critically, systemic reform.

The Anatomy of a recurring Catastrophe

The Chhindwara incident is a symptom of a deeply rooted and systemic pathology within India’s pharmaceutical regulatory framework. To understand why such tragedies recur, one must dissect the chain of failure that allows a known poison to be bottled and sold as medicine.

1. The Chemical Culprit: Diethylene Glycol (DEG)
DEG is a sweet-tasting, odorless, and colorless liquid used primarily as an industrial solvent and antifreeze. Its toxicity in humans is well-documented and brutal. When ingested, it is metabolized in the liver into compounds that cause severe metabolic acidosis, acute kidney failure, and neurological damage, often leading to a painful death. There is no safe consumption level, especially for children, whose smaller body mass makes them exponentially more vulnerable. The fact that a chemical with such a notorious history continues to be the agent of these tragedies underscores a catastrophic failure in basic quality control.

2. The Pathway of Contamination
The journey of DEG from an industrial warehouse to a child’s medicine bottle is a journey through multiple layers of negligence:

• The Raw Material Supplier: Pharmaceutical-grade propylene glycol (PG) is a safe and common solvent used in liquid medicines. However, DEG is a known and deadly impurity that can be present in industrial-grade PG. The first line of defense is for the manufacturer to source all raw materials from certified, reputable suppliers and to conduct rigorous in-house testing of every batch for contaminants like DEG upon receipt.

• The Manufacturer’s Failure: The primary responsibility lies with the drugmaker, Sresan Pharma in this case. Even if contaminated material enters their facility, it is their legal and ethical obligation to detect it. This involves testing the final formulated product before it is released for sale. Reports suggesting the DEG component in Coldrif was over 16%—against a permissible limit of less than 0.1%—point not to a minor oversight but to a complete and gross dereliction of duty. This indicates that mandatory quality control tests were either not performed, were performed with criminal incompetence, or their results were deliberately ignored.

• The Regulator’s Complicity: The state drug regulatory authority in Tamil Nadu, under whose jurisdiction Sresan Pharma operates, is supposed to be the final watchdog. It is mandated to conduct random checks on products from factories and the marketplace and to audit the manufacturer’s quality control processes. The fact that this highly contaminated syrup passed through this regulatory net exposes a profound failure in oversight.

The Root of the Problem: A Fractured and Feeble Regulatory Architecture

The central argument, powerfully made in the text, is that India’s drug regulatory system is fundamentally broken. The problem is not a lack of laws, but a fractured and politicized structure that prioritizes bureaucratic turf over human life.

The CDSCO-State Divide:
The core of this dysfunction is the bifurcated nature of drug regulation in India. The Central Drugs Standard Control Organisation (CDSCO) is a non-statutory body under the Union Health Ministry. Its authority is limited, and it holds no direct jurisdiction over the State Drug Regulatory Authorities, which operate under their respective state health departments.

This fragmentation creates a disastrous patchwork of standards and enforcement. A company can be shut down in one state for violations only to set up shop in another with a more lenient or corrupt regulatory environment. There is no single, powerful, national authority with the unified command and resources to enforce consistent Good Manufacturing Practices (GMP) across the country. This system is designed for buck-passing and opacity, not for accountability and safety.

Lack of Independence:
Furthermore, these regulatory bodies lack independence. They are subservient to their parent health ministries, making them vulnerable to political and commercial pressure. The “arm’s length” distance necessary for impartial, science-based regulation does not exist. The text’s demand that “Drug standard regulators must also maintain an arm’s length from governments for independence and effective oversight” is a critical one. When regulators are beholden to political masters, the interests of public health can easily be superseded by the interests of industry lobbies or the desire to project a facade of a booming “Pharmacy of the World.”

A Grisly Timeline of Failure

The Chhindwara deaths are not an anomaly; they are part of a grim pattern:

• 2022: The Gambia: The deaths of at least 70 children in Gambia were linked to cough syrups manufactured by an Indian company, Maiden Pharmaceuticals.

• 2022: Uzbekistan: Similar incidents were reported in Uzbekistan, again linked to Indian-made syrups.

• 2020 & 2019: Earlier instances of DEG poisoning were reported in Jammu and Gurugram.

• The 1988 Lentin Commission: Perhaps most damningly, a nearly identical DEG poisoning in Mumbai in 1988 killed 14 patients. The subsequent Lentin Commission report was scathing, indicting the company, the FDA, and health officials for “licensing a known poisonous drug,” “collusion,” and “callousness.” Its recommendations for a centralized, independent authority were largely ignored.

This timeline reveals a nation that has refused to learn from its own tragic history. Each commission report gathers dust, each political promise of reform fades, and the system remains unchanged, waiting for the next batch of poisoned syrup to claim its youngest and most vulnerable citizens.

The Path to Reform: What Must Be Done

The solution requires not just tinkering but a fundamental architectural overhaul, inspired by the very lesson the United States learned in 1938.

1. Create a Centralized, Independent Regulator: India needs a single, powerful, autonomous national drug authority. This body, let’s call it the National Drug Authority (NDA), must be statutory, independent of the health ministry, and have unified command over regulation, standard-setting, and enforcement across all states. It should be staffed by technical experts, not bureaucrats, and be funded directly by Parliament to ensure its operational freedom.

2. Mandate and Enforce Stringent Testing: The testing protocol for excipients, especially solvents like propylene glycol, must be made mandatory, non-negotiable, and subject to third-party audit. The use of Gas Chromatography, as recommended by the WHO, to detect DEG/EG should be a compulsory requirement for the release of every batch of liquid oral medication.

3. Implement a Track-and-Trace System: A digital, pan-India track-and-trace system for all pharmaceutical raw materials and finished products would bring transparency to the supply chain, making it harder for substandard or spurious products to enter the market.

4. Introduce Criminal Liability with Severe Punishment: The legal consequences for negligence leading to death must be severe. Company owners, quality control heads, and complicit regulators must face charges of culpable homicide not amounting to murder. Penalties must be financially crippling for the companies involved, serving as a genuine deterrent.

5. Empower and Educate Consumers: While the primary onus is on the system, public awareness is key. Doctors and consumers must be cautious about prescribing and using liquid medications for children, especially from lesser-known brands, and must report adverse effects immediately.

Conclusion: A Call for National Outrage

The deaths of the children in Chhindwara are a national shame. They died not from an incurable disease, but from a failure of governance, a collapse of accountability, and a chilling indifference that has persisted for decades. “Allowing manufacturers to cut corners,” as the text states, “is allowing them to cut down our children’s lives.”

The United States of 1937 looked at the corpses of its children and said, “Never again.” India, in 2025, stands at the same crossroads. We must, as a nation, choose to be horrified. We must channel our collective grief and anger into an unrelenting demand for a system that protects its most vulnerable. The memory of the children of Chhindwara, and all the children who have perished before them, must become the catalyst for creating a regulatory framework worthy of a nation that aspires to be a global leader. The reform of India’s drug regulatory system is not just a policy imperative; it is a moral one. The time for empty promises is over. The time for action is now.

Q&A: Unpacking India’s Drug Regulation Crisis

1. What is Diethylene Glycol (DEG) and why is it so deadly?
Diethylene Glycol (DEG) is a toxic industrial solvent primarily used in antifreeze and other commercial applications. It is sweet-tasting and odorless, making it difficult to detect when mixed into a solution. It is lethal to humans because the body metabolizes it into compounds that cause severe metabolic acidosis, acute kidney failure, and neurological damage. Even small amounts can be fatal, especially for children, and there is no antidote.

2. How does a known poison like DEG end up in children’s cough syrup?
DEG enters the medicine supply chain through a multi-stage failure:

• Fraudulent Supply: A raw material supplier may sell cheap, industrial-grade propylene glycol (which can contain DEG) as expensive, pharmaceutical-grade solvent.

• Manufacturer Negligence: The drug company fails to test the raw materials and the final product for this known contaminant, either to cut costs, due to incompetence, or deliberately.

• Regulatory Failure: The state drug inspectorate does not catch this lapse during its mandatory checks and audits, allowing the poisoned product to be sold.

3. What is the main structural problem with India’s drug regulatory system?
The main problem is its fragmented nature. India does not have a single, powerful national drug regulator. The central agency (CDSCO) has limited power and no direct control over state-level drug authorities, which operate independently under their respective state governments. This creates a patchwork of standards and enforcement, allowing manufacturers to sometimes exploit weaker regulatory regimes in certain states.

4. What was the “Lentin Commission” and why is it still relevant today?
The Lentin Commission was a judicial inquiry formed after a 1988 DEG poisoning incident in Mumbai that killed 14 people. Its report was a scathing indictment, highlighting corruption, collusion between drug manufacturers and regulators, and a complete failure of the regulatory system. Its core recommendation was for a centralized, independent drug authority. The fact that the same issues persist today, leading to nearly identical tragedies, shows that these critical recommendations were ignored, making the report a tragic and prophetic document.

5. What concrete steps can be taken to prevent such tragedies in the future?
A comprehensive solution requires:

• A Centralized Regulator: Establishing a single, autonomous, and statutorily empowered National Drug Authority with unified control over all drug regulation in India.

• Mandatory Testing: Making it legally compulsory for manufacturers to test every batch of raw material and finished product for contaminants like DEG using WHO-recommended methods.

• Severe Punishments: Introducing strict criminal liability, including charges of culpable homicide, for company executives and regulators whose negligence leads to death.

• Supply Chain Transparency: Implementing a digital track-and-trace system for pharmaceuticals to prevent the entry of spurious and substandard drugs into the market.